$75 million. Oversubscribed. For a platform most biotech investors haven't heard of — yet. Lycia Therapeutics, a South San Francisco biotech built on Nobel Prize-winning chemistry, closed its Series D on June 25. The round was co-led by Janus Henderson and Balyasny Asset Management, with participation from
London biotech RQ Bio raised $115M for RQB01, a long-acting antibody aiming to replace annual flu shots for high-risk patients.
The global clinical pipeline contains over 22,000 active compounds. Yet 90% of candidates fail. AI, regulatory reform, and new modalities are reshaping how drugs go from target discovery to commercial launch.
The WEF's 3C framework — combination, convergence, compounding — explains why the winners in tech are no longer the most advanced, but the most ready to integrate.
NewLimit raised $435M at $3.1B valuation for the first human trial of epigenetic reprogramming. A chronicle of the company's journey from seed to clinic.
Drug discovery timelines are compressing from a decade to eighteen months. A guide to the AI platforms and gene editing technologies rewriting the rules of pharmaceutical R&D.
The WEF's Top 10 Emerging Technologies report reveals a shift toward distributed systems — but every decentralized node creates a new central control point. A debate.
The $44 billion longevity market measures everything except whether extended lives feel worth living. A new concept called Joyspan is changing that — and capital is starting to follow.